S-acyl transferase ZDHHC13 modulates tumor microenvironment interactions to suppress metastasis in melanoma models.
Li. Hongjin H; Lyu. Jianke J; Sun. Yu Y; Yin. Chengqian C; Li. Yuewen Y; Chen. Weiqiang W; Foo. Suan-Sin SS; Wu. Xianfang X; Goding. Colin R CR; Chen. Shuyang S
Key Findings
- ZDHHC13 adds a palmitoyl group to CTNND1, stabilizing E‑cadherin and limiting melanoma cell metastasis.
- Higher ZDHHC13 activity reduces production of lysophosphatidylcholine, decreasing M2‑like tumor‑associated macrophages.
- In mouse models, boosting ZDHHC13 activity leads to smaller tumors and fewer metastases.
Practical Outcomes
- For biohackers and N=1 experimenters, this research does not provide actionable guidance on using palmitoyl‑dipeptide‑6 for health or performance. It is focused on a specific cancer‑related enzyme and its role in tumor spread, so it has no direct implications for longevity, metabolic health, or everyday supplement protocols.
Summary
The study shows that a protein called ZDHHC13 can add a fatty tag (palmitoylation) to another protein, which helps keep cells stuck together and reduces the spread of melanoma tumors. It also changes the tumor’s environment so fewer immune‑suppressing macrophages are present. This work is about cancer biology, not about the peptide palmitoyl‑dipeptide‑6 used in skin or health products.
Abstract
The intratumor microenvironment shapes the metastatic potential of cancer cells and their susceptibility to any immune response. Yet, the nature of the signals within the microenvironment that control anticancer immunity and how they are regulated is poorly understood. Here, using melanoma as a model, we investigate the involvement in metastatic dissemination and the immune-modulatory microenvironment of Protein S-Acyl Transferases as an underexplored class of potential therapeutic targets. We find that ZDHHC13 suppresses metastatic dissemination by palmitoylation of CTNND1, leading to stabilization of E-cadherin. Importantly, ZDHHC13 also reshapes the tumor immune microenvironment by suppressing lysophosphatidylcholine (LPC) synthesis in melanoma cells, leading to inhibition of M2-like tumor-associated macrophages that we show degrade E-cadherin via MMP12 expression. Consequently, ZDHHC13 activity suppresses tumor growth and metastasis in immunocompetent mice. Our study highlights the therapeutic potential of targeting the ZDHHC13-E-cadherin axis and its downstream metabolic and immune-modulatory mechanisms, offering additional strategies to inhibit melanoma progression and metastasis.
Study Information
pubmed
2025
2025-09-30T00:00:00.000Z
10.1172/jci188249